Cancer Center Dermatology Clinics Show High-Intensity Billing, Study Finds

When a cancer patient develops a blistering rash from a new immunotherapy or a suspicious lesion appears on sun-damaged skin, the dermatologists who step in are often invisible to the broader machinery of oncology. Yet a new analysis from one of the world’s leading cancer centers suggests that these specialists are doing far more cognitively demanding work per visit than their billing has traditionally been assumed to reflect. The study, published in the Archives of Dermatological Research, offers one of the first detailed quantitative portraits of how much physician work is generated by outpatient dermatology visits in a dedicated cancer care setting, and the answer carries implications for how hospitals decide which services to fund and expand.

The research team, led by Ian Nykaza and Alina Markova of the Dermatology Service at Memorial Sloan Kettering Cancer Center, together with colleagues at Weill Cornell Medical College, examined the work relative value units, or wRVUs, attached to more than thirteen thousand outpatient dermatology visits. The wRVU is the metric at the heart of American physician compensation: it is a standardized number assigned by Medicare to every evaluation and management encounter and every procedure, intended to quantify the physician work involved in caring for a patient. Because salaries, bonuses, and departmental budgets are frequently tied to wRVU production, the metric quietly shapes which clinical services hospitals consider financially sustainable.

To build their picture, the researchers conducted a retrospective review of 13,534 outpatient visits occurring between April 1, 2022, and April 1, 2023. They deliberately excluded inpatient consultations and procedure-only encounters, focusing instead on the routine outpatient clinic work that constitutes the bulk of subspecialty dermatology practice. Each visit was assigned to one of three subspecialty categories: cutaneous oncology, which covers skin cancers and premalignant lesions; cutaneous lymphoma, a rare group of cancers that present in the skin and require intricate diagnostic reasoning; and oncodermatology, the rapidly growing field that manages dermatologic adverse events triggered by modern cancer therapies such as checkpoint inhibitors and targeted agents. For every visit, the team tallied the wRVUs from evaluation and management codes and from any associated current procedural terminology codes.

The headline finding was a geometric mean of 1.76 wRVUs per visit across all three subspecialties, with a 95 percent confidence interval of 1.73 to 1.77. That figure may sound abstract, but in the grammar of American billing it signals consistently high-intensity encounters. The analysis of visit complexity levels makes the point even more clearly. Just over half of all visits, 51.6 percent, were billed at evaluation and management level 3, and nearly 40 percent, 39.9 percent, reached level 4. Oncodermatology stood out even within this already demanding mix: 53.7 percent of its visits were level 4 and 10.7 percent reached level 5, the highest complexity tier in the coding system. In practical terms, most patients walking into these clinics presented problems that required extensive data review, careful medical decision-making, and substantial physician time.

Perhaps the most consequential technical detail in the study is where the wRVUs actually came from. The majority were generated by evaluation and management codes rather than by procedures. This distinction matters because the economics of dermatology have long been dominated by procedural work, such as biopsies, excisions, and Mohs micrographic surgery, which generate robust technical revenue. Cognitive visits, by contrast, have historically been undervalued in the fee schedule, a disparity that prompted significant revisions to evaluation and management reimbursement in recent years. A subspecialty practice whose value derives mostly from cognitive work therefore looks weaker on a traditional revenue spreadsheet even when the clinical intensity per hour is high, a mismatch the authors argue deserves institutional attention.

The patient population behind these numbers underscores why the work is so complex. The 7,589 patients in the cohort had a mean age of 58.7 years, and by definition nearly all were navigating cancer or its aftermath. Cutaneous lymphoma patients often require serial skin examinations, staging discussions, and coordination with hematologic oncology. Cutaneous oncology patients include individuals with melanoma and high-risk nonmelanoma skin cancers whose surveillance demands meticulous, repeated assessment. Oncodermatology patients present some of the most diagnostically tangled scenarios in modern medicine: rashes, mucositis, and immune-mediated eruptions arising from therapies that cannot simply be stopped, because the drugs causing the skin toxicity may be the patient’s best chance at survival. Prior research cited by the authors has shown that dermatologic adverse events can lead to interruption of anticancer therapy, making rapid, expert dermatologic input a genuine component of cancer treatment rather than an ancillary comfort.

The study’s framing is explicitly financial as well as clinical. The authors write that the high billing intensity observed across cutaneous oncology, cutaneous lymphoma, and oncodermatology may reflect high-complexity, cognitively intensive care, and that these findings support further investigation into the financial sustainability of these subspecialties to justify broader institutional investment. That language reflects a real tension in academic medicine. As the population of cancer survivors in the United States continues to grow, demand for specialized skin care within oncology is rising, yet departments must compete for resources against services whose wRVU output is easier to demonstrate. Quantifying productivity in the standard currency of hospital finance is a step toward making the case that these clinics are not cost centers but high-value engines of complex care.

Methodologically, the study is a short report with clear limits that the authors and readers must keep in view. It captures a single year at a single tertiary cancer center, an institution whose case mix, coding practices, and payer environment may differ substantially from community oncology practices or general dermatology clinics. The geometric mean was used instead of the arithmetic mean, a statistically sensible choice given the right-skewed distribution of wRVU values, where a small number of very high-billing visits can distort averages. The researchers also compared the sources of wRVUs across the three subspecialties, providing a granular view of whether value came from office visits, procedures, or both. No new datasets were generated or analyzed beyond the study itself, and the work was supported in part by a National Cancer Institute cancer center support grant, with institutional review board approval at Memorial Sloan Kettering.

What makes the findings resonate beyond dermatology is the broader question they raise about how medicine values thinking. The wRVU system was designed to measure physician work, but its application has repeatedly revealed blind spots, particularly for specialties whose contribution is diagnostic reasoning, care coordination, and the prevention of treatment interruptions rather than the performance of billable procedures. As cancer therapies become more powerful and more toxic, the cognitive load carried by supportive care specialists grows in parallel. A patient whose severe eczematous eruption is correctly managed may keep receiving a therapy that adds years to their life, an outcome no current billing code fully captures.

For now, the study stands as a quantitative baseline. It documents that at one major cancer center, subspecialty dermatology generates high wRVU intensity per visit, driven overwhelmingly by evaluation and management work and concentrated at the upper complexity tiers. Whether that pattern holds across other institutions, how it translates into actual revenue after costs, and how administrators weigh cognitive intensity against procedural volume remain open questions the authors explicitly flag for future research. But the message to hospital leadership is difficult to ignore: the dermatologists managing the skin complications of cancer care are performing some of the most complex outpatient work in the building, and the numbers now exist to prove it.

Subject of Research: Work relative value unit generation and visit complexity in subspecialty outpatient dermatology at a tertiary cancer center

Article Title: Landscape of outpatient dermatology work relative value units (wRVUs) at a tertiary cancer center

Article References: Landscape of outpatient dermatology work relative value units (wRVUs) at a tertiary cancer center. (n.d.). https://doi.org/10.1007/s00403-026-04901-3

Image Credits: AI Generated

DOI: 10.1007/s00403-026-04901-3

Keywords: dermatology, oncodermatology, cutaneous oncology, cutaneous lymphoma, work relative value units, wRVU, visit complexity, evaluation and management, billing intensity, cancer care, healthcare delivery, financial sustainability